Revenue Components (Tables)

6 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

The following table provides information about the Company’s revenues (in thousands):


	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
Revenues:
Product revenue, net:
ORGOVYX	$	43,319	$	18,663	$	79,353	$	29,142
MYFEMBREE	6,403		629		10,402		1,704
Richter product supply and royalties	225		1,771		1,543		1,771
Total product revenue, net	49,947		21,063		91,298		32,617
Pfizer collaboration revenue:
Amortization of upfront payment	20,974		20,974		41,948		41,948
Amortization of regulatory milestones	33,603		4,198		37,770		12,733
Total Pfizer collaboration revenue	54,577		25,172		79,718		54,681
Accord license revenue	—		—		50,000		—
Richter license and milestone revenue	300		31,667		300		31,667
Total revenues	$	104,824	$	77,902	$	221,316	$	118,965

Summary Of Categories Of Discounts And Allowances

The activities and ending balances for each significant category of discounts and allowances (which constitutes variable consideration) for the six months ended September 30, 2022 were as follows (in thousands):


	Reserve -government and other incentives		Chargebacks and administrative fees		Returns		Sales Discounts		Total
Balance as of March 31, 2022	$	13,734	$	2,628	$	3,028	$	486	$	19,876
Provision related to sales in the current year	54,248		14,169		1,838		2,627		72,882
Adjustments related to prior year sales	1,050		(741)		—		—		309
Credits and payments made during the current year	(39,056)		(12,273)		(5)		(2,481)		(53,815)
Balance as of September 30, 2022	$	29,976	$	3,783	$	4,861	$	632	$	39,252

The total reserves described above are summarized as components of the Company’s unaudited condensed consolidated balance sheets as follows (in thousands):


	September 30, 2022		March 31, 2022
Reduction of accounts receivable, net	$	632	$	486
Component of accrued expenses and other current liabilities	38,620		19,390
Total revenue-related reserves	$	39,252	$	19,876